U.S. launches extensive Alzheimer's studies

U.S. launches extensive alzheimer's studies
5-year, $55 million effort will look at exercise, drug treatment as therapies for early disease.

(HealthDay)—Four U.S. government-funded clinical trials will search for new therapies for Alzheimer's disease.

The five-year effort will look at drug and exercise treatments for patients with early stage disease, test if the prazosin can reduce agitation in Alzheimer's patients, and examine a new approach to speed testing of drugs in .

The trials, which could cost as much as $55 million, are projects of the Alzheimer's Disease Cooperative Study (ADCS), a of and clinics established in 1991 by the U.S. National Institutes of Health.

The consortium, which includes more than 70 sites in the United States and Canada, focuses on research of diagnosis and treatment methods that might not be tested by the drug industry.

The four studies are among efforts to accomplish the research goals outlined in the National Plan to Address Alzheimer's Disease, which was announced in May 2012. The plan calls for a coordinated and focused effort in research, care and services for Alzheimer's and related types of . The goal is to find ways to prevent and effectively treat Alzheimer's by 2025.

"The ADCS is a key initiative in the federal program to discover, develop and test new Alzheimer's treatments and . Over the years, it has proved invaluable in advancing our understanding about the disease and how to conduct research in this challenging area," Dr. Richard Hodes, director of the National Institute on Aging, said in an NIH news release.

"I am particularly excited that this round of studies will use what we have learned by testing interventions pre-symptomatically, as early as we can in the development of the disease, where we now think the best hope lies for keeping Alzheimer's at bay," he added.

More information: The Alzheimer's Association has more about Alzheimer's disease.

add to favorites email to friend print save as pdf

Related Stories

Pfizer and J&J end development of Alzheimer's drug

Aug 06, 2012

Pfizer Inc. and Johnson & Johnson say they are ending development of a once-promising drug designed to treat Alzheimer's disease after the treatment failed in two late-stage clinical trials.

Recommended for you

Putting dementia carers in control

Sep 18, 2014

Experts will explore how improved support and powers for people caring for loved-ones with dementia can improve quality of life for both patients and carers around the UK.

Lilly, AstraZeneca team up on Alzheimer's drug

Sep 16, 2014

Eli Lilly and Co. plans to pay up to $500 million to fellow drugmaker AstraZeneca as part of a collaboration to develop and sell a potential Alzheimer's disease treatment that is in the early stages of clinical testing.

User comments